logo
Share SHARE
FONT-SIZE Plus   Neg

Appeals Court Says Rituxan, Avastin Do Not Infringe Sanofi Patents

An appeals court on Thursday upheld a lower court's ruling that the cancer drugs Rituxan and Avastin of Swiss drug maker Roche Holding AG's (RHHBY.PK) Genentech unit and biotechnology firm Biogen Idec Inc. (BIIB) do not infringe two patents of French drug maker Sanofi SA (SNY,SNYNF.PK).

Genentech's Avastin, which had sales of 5.29 billion Swiss francs in 2011, is a blockbuster drug for treatment of cancers related to colon, lung, kidney and brain. Rituxan had sales of 6.01 billion Swiss francs in 2011. Rituxan is currently co-marketed by Biogen Idec and Genentech in the U.S.

In a ruling posted on the court's website, the U.S. Court of Appeals for the Federal Circuit said that Sanofi's '522 and '140 patents were not infringed by Genentech and Biogen. The court ruled that the district court had not erred in its judgment.

In October 2008, Sanofi filed a lawsuit for infringement of the two patents, alleging that Genentech and Biogen made use of an infringing enhancer in producing the antibody-based drugs Rituxan and Avastin.

SNY closed Thursday's trading at $38.45, down $0.23 or 0.59 percent on a volume of 1.86 million shares.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Chipotle Mexican Grill (CMG) is giving away free food and drinks this September as the restaurant chain still struggles to boost its sales that has been sluggish after outbreaks of E.coli, salmonella and norovirus at its restaurants. The chain is offering free kids meals every Sunday in September... It seems that Colonel Sanders' nephew unknowingly disclosed the secret blend of 11 herbs and spices behind KFC's fried chicken, which the food chain touts as the most heavily-guarder food recipe in the world. However, KFC executives refutes the report and insist that its 11-spice "Original Recipe"... QSR Brands, Malaysia's largest fast food operator, is planning for an initial public offering worth more than $400 million, according to the Wall Street Journal.
comments powered by Disqus
Follow RTT